Zydus Cadila gets USFDA’s nod for Potassium Chloride Extended-Release Capsules

13 Mar 2019 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Potassium Chloride Extended-Release Capsules USP (US RLD - Micro-K Extended-Release Capsules), 8 mEq (600 mg) and 10 mEq (750 mg). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. Potassium helps your cells, kidneys, heart, muscles and nerves work properly. Some conditions that can lower the body's potassium level include severe prolonged diarrhoea and vomiting, hormone problems such as hyperaldosteronism, or treatment with ‘water pills’/diuretics.

The group now has 254 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

932.30 0.85 (0.09%)
08-Dec-2025 11:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.05
Dr. Reddys Lab 1275.15
Cipla 1511.05
Zydus Lifesciences 932.30
Lupin 2089.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×